BioXcel Therapeutics Inc.

2.85
0.21 (7.95%)
At close: Feb 10, 2025, 11:46 AM
undefined%
Bid 2.83
Market Cap 8.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -32.64
PE Ratio (ttm) -0.09
Forward PE n/a
Analyst Buy
Ask 2.87
Volume 245,595
Avg. Volume (20D) 118,620
Open 2.89
Previous Close 2.64
Day's Range 2.74 - 3.15
52-Week Range 2.56 - 61.12
Beta undefined

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 74
Stock Exchange NASDAQ
Ticker Symbol BTAI

Analyst Forecast

According to 4 analyst ratings, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 1023.44% from the latest price.

Buy 50.00%
Hold 25.00%
Sell 25.00%
Stock Forecasts

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
4 days ago
-37.57%
BioXcel Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
1 month ago
-17.78%
BioXcel Therapeutics shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform and cut its price target from $7 to $0.25.